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Autoinflammatory diseases (AIDs) are monogenic disorders [1] char-
acterized by overproduction of IL-1β. Remission, prevention of com-
plications, control of inflammation, a good quality of life are goals of
the treatment. A personalized treatment must be started preco-
ciously [2] and approved by clinicians, patients and their families,
considering children in these long-lasting treatment decisions. A
common therapeutic approach is effective in multifactorial AIDs,
where inflammatory cytokines are increased by different triggers, as
sJIA, Kawasaki disease, HLH, IBD, Steven Johnsons Syndrome, auto-
immune diseases: the infusion of high doses of IVIG, modifying cyto-
kines and immune response. IVIG are effective in the resolution of
fever, hepatitis and/or cholestasis also if triggered by infections [3].
Anti-TNF-α drugs are effective in IBD and Bechet disease; Infliximab
in the control of fever in refractory KD, not improving coronary artery
lesions (CAL). Anakinra, IL-1 receptor antagonist, is effective on clin-
ical manifestations and CAL [4-5]. Treatment of sJIA improved with
anti-IL-1 (Canakinumab, Anakinra) and anti-IL-6 (Roactemra) bio-
logical drugs. The early employ of Canakinumab in a “therapeutic
window” increases the possibility to gain the remission [6]. Systemic
Lupus Erythematous and monogenic interferonopathies are success-
fully treated with JAK inhibitors, a high selective treatment. Remis-
sion is now evaluated by clinimetrics to define the efficacy of
treatment.
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The scientific literature reports an increasing number of actions
aimed at providing mobile robots that allow telepresence experi-
ences to bed-ridden adult patients [1]. A recent review published in
BJM Open [2] shows that the use of such robots is increasing very
quickly. The nationality of the authors of the articles analyzed in this
work is mainly Italy. The use of humanoid and empathic robots such
as Nao and Pepper is spreading also in Italian pediatric hospitals. It
follows that it is possible and appropriate, as already happens for
adults, to use these robots not only for rehabilitation, surgery and
distraction [Dawe et al 2019] but also to promote inclusion, by
employing them as a telepresence robot. In this case it is no longer
the medical-nursing staff that "guides" the robot used for the patient
but the patient himself who uses the humanoid robot as a "courtesy
body", a robotic avatar, controlled from the bed or from the stay. At
present, applications of this kind reported in literature are very scarce
and focused exclusively in protected contexts (hospitals and other
places of care) but not in other environments (museums, schools,
homes for holidays, mountain refuges). The number of articles con-
taining the keywords "robot" and "telepresence" has increased expo-
nentially in the period 2000-2017. Yet, nothing has been published
to date regarding the developmental age. The aim of this work was
therefore to verify whether, within a pediatric hospital, humanoid ro-
bots can have an inclusive role in contexts typical of the develop-
mental age (school, sports, oratory, summer camps). In particular 3
models of humanoid robots were used in extra-hospital settings and
remote-controlled by a underage patient. From these preliminary ex-
periences, telepresence robotics carried out with humanoid and em-
pathic robots seems to be promising for hospitalized children.
Entrusting a small robot avatar use to each underage patient, with
the goal to reach an earlier inclusion, is not only technically possible
but also sustainable from the social, economic and environmental
points of view. The use of BCI (Brain Computer Interface) technolo-
gies in children could make this opportunity universal.
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Kawasaki disease (KD) is an acute, systemic vasculitis [1,2]. According
to the “Revised International Chapel Hill Consensus Conference No-
menclature of Vasculitides” of 2012, its target are small and medium
diameter vessels in each organ and apparatus. (3) KD is a self-limited
disease with unknown, probably multi-factor, aetiology, which pri-
marily affects infants and children under five years. Diagnosis of
